Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis
Saved in:
| Published in: | PLOS ONE |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis
- Correction: ESG rating disagreement and bank loan availability: Evidence from China
- Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis
- Metabolic profiling of human melanoma cell lines with high and low metastatic capacity by 1H-NMR spectroscopy
- Correction: A treadmill training program in a gamified virtual reality environment combined with transcranial direct current stimulation in Parkinson’s Disease: Study protocol for a randomized controlled trial
- Correction: A treadmill training program in a gamified virtual reality environment combined with transcranial direct current stimulation in Parkinson’s Disease: Study protocol for a randomized controlled trial
- Metabolite profiling of saliva for the discrimination of Behcet’s disease, Sjögren’s syndrome, and recurrent aphthous stomatitis